News

ERIS Lifesciences has allotted 24,396 equity shares under ESOP on 11 May 2026. The paid-up share capital of the Company accordingly stands increased from Rs 13,85,42,887/- (13,85,42,887 equity shares of Re 1/- each) to Rs 13,85,67,256/- (13,85,67,256 equity shares of Re 1/- each).

Eris Lifesciences has received affirmation in credit ratings for non convertible debentures and bank facilities at IND AA; Stable/ IND A1+ from India Ratings and Research. The company`s issuer rating has been affirmed at IND AA; Stable.

ERIS Lifesciences has appointed Vineet Varma (DIN: 11600100) as an Additional Director (Non-executive, Independent) of the Company for a term of five years, effective from 14 March 2026, subject to the approval of the members.Powered by Capital Market - Live News

ERIS Lifesciences has allotted 19,624 equity shares under ESOP on 12 March 2026. With this allotment, the paid up equity share capital stands increased to Rs. 13,85,42,887/- (13,85,42,887 equity shares of Re. 1/- each).Powered by Capital Market - Live News

Net profit of ERIS Lifesciences rose 19.05% to Rs 99.72 crore in the quarter ended December 2025 as against Rs 83.76 crore during the previous quarter ended December 2024. Sales rose 10.91% to Rs 800.89 crore in the quarter ended December 2025 as against Rs 722.12 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales800.89722.12 11 OPM %35.1634.66 - PBDT232.93197.36 18 PBT162.59116.36 40 NP99.7283.76 19 Powered by Capital Market - Live News